Treatment with 0.1 and 1 μM CsA (doses corresponding to in vivo blood concentrations) leads to downregulation of gm-csf mRNA level in GL261 glioma cells (Fig. 4E). The gene discussed is CSF2; the disease is central nervous system cancer.